Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study

Tsutomu Takeuchi, Yoshiya Tanaka, Koichi Amano, Daisuke Hoshi, Masao Nawata, Hayato Nagasawa, Eri Sato, Kazuyoshi Saito, Yuko Kaneko, Shunsuke Fukuyo, Takahiko Kurasawa, Kentaro Hanami, Hideto Kameda, Hisashi Yamanaka

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Objectives: To evaluate the effectiveness and safety of tocilizumab in RA patients in clinical practice. Methods: We observed 232 consecutive RA patients who began tocilizumab in three rheumatology centres in Japan for 52 weeks. Clinical, radiographic and functional status and safety were evaluated. Results: Mean age of the 232 patients was 59.1 years, mean duration of disease was 12.4 years and average DAS using the 28-joint count (DAS-28) was 5.6. Although 62.8% of the patients had been treated previously with anti-TNF biologics, clinical remission at Week 52 was achieved in 43.7%, radiographic non-progression in 62.8% and functional remission in 26.4%. Retention rate at Week 52 was 71.1%, and the same for those with or without previous anti-TNF treatment. Adverse drug reactions leading to tocilizumab discontinuation were observed in 15.5% of patients, the most frequent adverse drug reaction being pneumonia in eight cases. On multivariate logistic regression analysis, DAS-28, HAQ-disability index (HAQ-DI), concomitant MTX and concomitant glucocorticoids (GCs) were predictive variables for clinical remission at Week 52 of tocilizumab treatment. In particular, HAQ-DI was found to be a predictive variable for remission of all three types-clinical, radiographic and functional-at Week 52 of tocilizumab treatment. Conclusions: In daily clinical practice, tocilizumab exhibited excellent effectiveness in established RA patients, some of whom had failed to respond to previous anti-TNF treatment. Although further detailed safety findings are required, this study provides valuable real-world findings on the management of RA with tocilizumab.

Original languageEnglish
Article numberker221
Pages (from-to)1908-1915
Number of pages8
JournalRheumatology
Volume50
Issue number10
DOIs
Publication statusPublished - 2011 Oct

Fingerprint

ametantrone
Rheumatoid Arthritis
amsonic acid
Drug-Related Side Effects and Adverse Reactions
Safety
Joints
Rheumatology
Therapeutics
tocilizumab
Biological Products
Glucocorticoids
Pneumonia
Japan
Logistic Models
Regression Analysis

Keywords

  • Health assessment questionnaire
  • Joint destruction
  • Remission
  • Rheumatoid arthritis
  • Tocilizumab

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. / Takeuchi, Tsutomu; Tanaka, Yoshiya; Amano, Koichi; Hoshi, Daisuke; Nawata, Masao; Nagasawa, Hayato; Sato, Eri; Saito, Kazuyoshi; Kaneko, Yuko; Fukuyo, Shunsuke; Kurasawa, Takahiko; Hanami, Kentaro; Kameda, Hideto; Yamanaka, Hisashi.

In: Rheumatology, Vol. 50, No. 10, ker221, 10.2011, p. 1908-1915.

Research output: Contribution to journalArticle

Takeuchi, T, Tanaka, Y, Amano, K, Hoshi, D, Nawata, M, Nagasawa, H, Sato, E, Saito, K, Kaneko, Y, Fukuyo, S, Kurasawa, T, Hanami, K, Kameda, H & Yamanaka, H 2011, 'Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study', Rheumatology, vol. 50, no. 10, ker221, pp. 1908-1915. https://doi.org/10.1093/rheumatology/ker221
Takeuchi, Tsutomu ; Tanaka, Yoshiya ; Amano, Koichi ; Hoshi, Daisuke ; Nawata, Masao ; Nagasawa, Hayato ; Sato, Eri ; Saito, Kazuyoshi ; Kaneko, Yuko ; Fukuyo, Shunsuke ; Kurasawa, Takahiko ; Hanami, Kentaro ; Kameda, Hideto ; Yamanaka, Hisashi. / Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. In: Rheumatology. 2011 ; Vol. 50, No. 10. pp. 1908-1915.
@article{6f98a26f24644477b5094c584e96a203,
title = "Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study",
abstract = "Objectives: To evaluate the effectiveness and safety of tocilizumab in RA patients in clinical practice. Methods: We observed 232 consecutive RA patients who began tocilizumab in three rheumatology centres in Japan for 52 weeks. Clinical, radiographic and functional status and safety were evaluated. Results: Mean age of the 232 patients was 59.1 years, mean duration of disease was 12.4 years and average DAS using the 28-joint count (DAS-28) was 5.6. Although 62.8{\%} of the patients had been treated previously with anti-TNF biologics, clinical remission at Week 52 was achieved in 43.7{\%}, radiographic non-progression in 62.8{\%} and functional remission in 26.4{\%}. Retention rate at Week 52 was 71.1{\%}, and the same for those with or without previous anti-TNF treatment. Adverse drug reactions leading to tocilizumab discontinuation were observed in 15.5{\%} of patients, the most frequent adverse drug reaction being pneumonia in eight cases. On multivariate logistic regression analysis, DAS-28, HAQ-disability index (HAQ-DI), concomitant MTX and concomitant glucocorticoids (GCs) were predictive variables for clinical remission at Week 52 of tocilizumab treatment. In particular, HAQ-DI was found to be a predictive variable for remission of all three types-clinical, radiographic and functional-at Week 52 of tocilizumab treatment. Conclusions: In daily clinical practice, tocilizumab exhibited excellent effectiveness in established RA patients, some of whom had failed to respond to previous anti-TNF treatment. Although further detailed safety findings are required, this study provides valuable real-world findings on the management of RA with tocilizumab.",
keywords = "Health assessment questionnaire, Joint destruction, Remission, Rheumatoid arthritis, Tocilizumab",
author = "Tsutomu Takeuchi and Yoshiya Tanaka and Koichi Amano and Daisuke Hoshi and Masao Nawata and Hayato Nagasawa and Eri Sato and Kazuyoshi Saito and Yuko Kaneko and Shunsuke Fukuyo and Takahiko Kurasawa and Kentaro Hanami and Hideto Kameda and Hisashi Yamanaka",
year = "2011",
month = "10",
doi = "10.1093/rheumatology/ker221",
language = "English",
volume = "50",
pages = "1908--1915",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study

AU - Takeuchi, Tsutomu

AU - Tanaka, Yoshiya

AU - Amano, Koichi

AU - Hoshi, Daisuke

AU - Nawata, Masao

AU - Nagasawa, Hayato

AU - Sato, Eri

AU - Saito, Kazuyoshi

AU - Kaneko, Yuko

AU - Fukuyo, Shunsuke

AU - Kurasawa, Takahiko

AU - Hanami, Kentaro

AU - Kameda, Hideto

AU - Yamanaka, Hisashi

PY - 2011/10

Y1 - 2011/10

N2 - Objectives: To evaluate the effectiveness and safety of tocilizumab in RA patients in clinical practice. Methods: We observed 232 consecutive RA patients who began tocilizumab in three rheumatology centres in Japan for 52 weeks. Clinical, radiographic and functional status and safety were evaluated. Results: Mean age of the 232 patients was 59.1 years, mean duration of disease was 12.4 years and average DAS using the 28-joint count (DAS-28) was 5.6. Although 62.8% of the patients had been treated previously with anti-TNF biologics, clinical remission at Week 52 was achieved in 43.7%, radiographic non-progression in 62.8% and functional remission in 26.4%. Retention rate at Week 52 was 71.1%, and the same for those with or without previous anti-TNF treatment. Adverse drug reactions leading to tocilizumab discontinuation were observed in 15.5% of patients, the most frequent adverse drug reaction being pneumonia in eight cases. On multivariate logistic regression analysis, DAS-28, HAQ-disability index (HAQ-DI), concomitant MTX and concomitant glucocorticoids (GCs) were predictive variables for clinical remission at Week 52 of tocilizumab treatment. In particular, HAQ-DI was found to be a predictive variable for remission of all three types-clinical, radiographic and functional-at Week 52 of tocilizumab treatment. Conclusions: In daily clinical practice, tocilizumab exhibited excellent effectiveness in established RA patients, some of whom had failed to respond to previous anti-TNF treatment. Although further detailed safety findings are required, this study provides valuable real-world findings on the management of RA with tocilizumab.

AB - Objectives: To evaluate the effectiveness and safety of tocilizumab in RA patients in clinical practice. Methods: We observed 232 consecutive RA patients who began tocilizumab in three rheumatology centres in Japan for 52 weeks. Clinical, radiographic and functional status and safety were evaluated. Results: Mean age of the 232 patients was 59.1 years, mean duration of disease was 12.4 years and average DAS using the 28-joint count (DAS-28) was 5.6. Although 62.8% of the patients had been treated previously with anti-TNF biologics, clinical remission at Week 52 was achieved in 43.7%, radiographic non-progression in 62.8% and functional remission in 26.4%. Retention rate at Week 52 was 71.1%, and the same for those with or without previous anti-TNF treatment. Adverse drug reactions leading to tocilizumab discontinuation were observed in 15.5% of patients, the most frequent adverse drug reaction being pneumonia in eight cases. On multivariate logistic regression analysis, DAS-28, HAQ-disability index (HAQ-DI), concomitant MTX and concomitant glucocorticoids (GCs) were predictive variables for clinical remission at Week 52 of tocilizumab treatment. In particular, HAQ-DI was found to be a predictive variable for remission of all three types-clinical, radiographic and functional-at Week 52 of tocilizumab treatment. Conclusions: In daily clinical practice, tocilizumab exhibited excellent effectiveness in established RA patients, some of whom had failed to respond to previous anti-TNF treatment. Although further detailed safety findings are required, this study provides valuable real-world findings on the management of RA with tocilizumab.

KW - Health assessment questionnaire

KW - Joint destruction

KW - Remission

KW - Rheumatoid arthritis

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=80053141949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053141949&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/ker221

DO - 10.1093/rheumatology/ker221

M3 - Article

C2 - 21752873

AN - SCOPUS:80053141949

VL - 50

SP - 1908

EP - 1915

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 10

M1 - ker221

ER -